Twice a day
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer
Ayrmid, Family Turdidae (organism), Twice a day, gene therapy, Carlyle, High, Bluebird Bio, Capital
Halozyme Therapeutics Abandons $2.1 Billion Acquisition Bid for Evotec Due to Lack of Engagement
Halozyme Therapeutics, Evotec, acquisition bid, withdrawal, lack of engagement, biotech industry
Evotec Shares Soar as Private Equity Firm Triton Considers Takeover Bid
Evotec, Triton Partners, takeover bid, private equity, drug development, pharmaceuticals
Vanda Pharmaceuticals Rejects Cycle’s Second Takeover Bid Amid FDA Rejection of Tradipitant
Vanda Pharmaceuticals, Cycle Pharmaceuticals, takeover bid, FDA rejection, tradipitant, gastroparesis, biopharma, acquisition offer